A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

Clinical trial NCT05473195 · COMPLETED

Trial details

NCT number: NCT05473195
Sponsor: TASK Applied Science
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)

Start date: 2022-12-06
Primary completion: 2024-04-16
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.